Cardiol Therapeutics Inc. (CRDL) Form 6-K — Sep 10, 2026
Cardiol Therapeutics filed a 6-K containing its Development Agreement with Clinical Academic Research Organization, S.A. de C.V. (CARO), under which CARO performs scientific experimentation, research, drug formulation and discovery activities on Cardiol's compounds being developed for the treatment of heart failure, per a Development Plan attached as an exhibit.
Key figures
- Warrant expiry
- August 31, 2022
- Shares reserved
- 824,000 Class A shares, approximately 3.2% of outstanding shares on a fully diluted basis
- Caro invoice usd
- US$475,741.50 (dated 2018-09-05)
- Cash payment usd
- US$400,000 due by November 30, 2018
- Warrant exercise price
- $4.00 per share
- Caro compensation warrants
- 824000
- Contractor response period
- 15 business days
- Rejection notice period days
- 30
- Competitive bid threshold usd
- $50,000
- Errors omissions insurance cad
- CAN$4 million
- Product liability insurance cad
- CAN$1 million
- Development activities value usd
- US$3,000,000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.